These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16921451)

  • 1. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis.
    Gwak HS; Youn SM; Chang U; Lee DH; Cheon GJ; Rhee CH; Kim K; Kim HJ
    Minim Invasive Neurosurg; 2006 Jun; 49(3):127-34. PubMed ID: 16921451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated stereotactic radiation therapy for skull base and upper cervical chordoma and chondrosarcoma: preliminary results.
    Gwak HS; Yoo HJ; Youn SM; Chang U; Lee DH; Yoo SY; Rhee CH
    Stereotact Funct Neurosurg; 2005; 83(5-6):233-43. PubMed ID: 16601376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CyberKnife stereotactic radiotherapy for spinal tumors: value of computed tomographic myelography in spinal cord delineation.
    Thariat J; Castelli J; Chanalet S; Marcie S; Mammar H; Bondiau PY
    Neurosurgery; 2009 Feb; 64(2 Suppl):A60-6. PubMed ID: 19165075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
    Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
    Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
    Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases.
    Leiva-Salinas C; Muttikkal TJE; Flors L; Puig J; Wintermark M; Patrie JT; Rehm PK; Sheehan JP; Schiff D
    AJR Am J Roentgenol; 2019 Feb; 212(2):425-430. PubMed ID: 30422717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
    Torigian DA; Lopez RF; Alapati S; Bodapati G; Hofheinz F; van den Hoff J; Saboury B; Alavi A
    Hell J Nucl Med; 2011; 14(1):8-14. PubMed ID: 21512658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inferior glucose metabolism and chemosensitivity of post-radiotherapy local recurrence in comparison with distant metastases as assessed by sequential (18)F-FDG PET/CT imaging.
    Sun X; Zhao F; Sun L; Li S; Li W; Zhang X; Xing L
    Ann Nucl Med; 2014 Aug; 28(7):610-6. PubMed ID: 24838784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?
    Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M
    J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma.
    Zheng XK; Chen LH; Wang QS; Wu HB; Wang HM; Chen YQ; Yan WP; Li QS; Xu YK
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1381-8. PubMed ID: 17869450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
    Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
    Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer.
    Brandmaier P; Purz S; Bremicker K; Höckel M; Barthel H; Kluge R; Kahn T; Sabri O; Stumpp P
    PLoS One; 2015; 10(11):e0141684. PubMed ID: 26551527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.